457
Views
7
CrossRef citations to date
0
Altmetric
Drug Evaluation

An evaluation of tofacitinib for the treatment of psoriatic arthritis

, &
Pages 1953-1960 | Received 18 Mar 2019, Accepted 15 Aug 2019, Published online: 28 Aug 2019

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Akpabio Akpabio & Adewale Adebajo. (2022) Evaluating upadacitinib for the treatment of psoriatic arthritis. Expert Opinion on Pharmacotherapy 23:2, pages 169-173.
Read now

Articles from other publishers (6)

Pooja Mathur, Ravinder Verma, Manish Kumar, Vikas Jhawat, Rohit Dutt & Shailendra Bhatt. (2023) Current Remedial Strategies for the Treatment of Rheumatoid Arthritis through the Oral Route with Janus Kinase Inhibitors. Drug Delivery Letters 13:1, pages 13-23.
Crossref
Zhenwu Yang, Yujia Tian, Yue Kong, Yushan Zhu & Aixia Yan. (2022) Classification of JAK1 Inhibitors and SAR Research by Machine Learning Methods. Artificial Intelligence in the Life Sciences 2, pages 100039.
Crossref
Ji Wen, Huifang Hu, Menglin Chen, Hang Yang, Yi Zhao & Yi Liu. (2021) Role of Janus Kinase (JAK) Inhibitor in Autoimmune Ocular Inflammation: A Systematic Review. Journal of Immunology Research 2021, pages 1-9.
Crossref
Arvin Ighani, Jorge R. Georgakopoulos & Jensen Yeung. (2020) Tofacitinib for the treatment of psoriasis and psoriatic arthritis. Giornale Italiano di Dermatologia e Venereologia 155:4.
Crossref
Vijayabhaskar Veeravalli, Ranjeet P. Dash, Jennifer A. Thomas, R. Jayachandra Babu, Lakshmi Mohan Vamsi Madgula & Nuggehally R. Srinivas. (2020) Critical Assessment of Pharmacokinetic Drug–Drug Interaction Potential of Tofacitinib, Baricitinib and Upadacitinib, the Three Approved Janus Kinase Inhibitors for Rheumatoid Arthritis Treatment. Drug Safety 43:8, pages 711-725.
Crossref
Vijayabhaskar Veeravalli & Ranjeet P. Dash. (2019) “Tofacitinib Is a Mechanism-Based Inactivator of Cytochrome P450 3A4”: Revisiting the Significance of the Epoxide Intermediate and Glutathione Trapping. Chemical Research in Toxicology 33:2, pages 281-282.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.